Kymera Therapeutics, Inc. (KYMR)
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)
Country: United States
Exchange: NASDAQ
Market cap: $9.79B
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 3, 2026
Profit #1355 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 6.5% | 5.8% | 5.5% | 6.3% |
Growth #284 of 1484 companies
Payout #1117 of 1484 companies
Safety #722 of 1484 companies
Price #1388 of 1484 companies
